Tom's of Maine toothpaste made with bacteria-contaminated water, says FDA - goodmorningamerica.com
FDA reports that Tom's of Maine toothpaste was made with bacteria-contaminated water, raising safety concerns.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 3, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. All manufacturers and distributors of Tom's of Maine toothpaste. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediate action required.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed. Regulated niches like Pharmaceutical Manufacturing (FDA/DEA) move faster than most operators can track by hand, which is why Aforeworn watches the official sources for you and flags every material change the moment it appears.
What changed
FDA's identification of bacteria contamination in the production process.
Who it affects
All manufacturers and distributors of Tom's of Maine toothpaste.
What you must do
Immediate cessation of sales and distribution of affected products; initiate a recall if necessary.
Deadline
Immediate action required.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- FDA Introduces ‘PreCheck’ Plan to Strengthen US Drug Facilities - Bloomberg Law News
- AbbVie, AstraZeneca lose appeal in Louisiana 340B contract pharmacy fight - endpoints.news
- Florida Compounding Pharmacy Punished by Federal Court - Medtruth
- Biden administration and drug manufacturer ask court to block suspension of mifepristone approval - SCOTUSblog
- FCC Holds Calls About Free Clinical Pharmaceutical Trials Are Not “Advertising” Under the TCPA - Consumer Financial Services Law Monitor